{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:13:02Z","timestamp":1768871582443,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T00:00:00Z","timestamp":1637366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Over the past decades, remarkable advancements in systemic drug therapy have improved the prognosis of patients with bone metastases. Individualization is required in external beam radiotherapy (EBRT) for bone metastases according to the patient\u2019s prognosis. To establish individualized EBRT for bone metastases, we investigated factors that affect the local control (LC) of bone metastases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between January 2010 and December 2019, 536 patients received EBRT for 751 predominantly osteolytic bone metastases. LC at EBRT sites was evaluated with a follow-up computed tomography. The median EBRT dose was biologically effective dose (BED<jats:sub>10<\/jats:sub>) (39.0) (range of BED<jats:sub>10<\/jats:sub>: 14.4\u201371.7\u00a0Gy).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median follow-up time and median time of computed tomography follow-up were 11 (range 1\u2013123) months and 6 (range 1\u2013119) months, respectively. The 0.5- and 1-year overall survival rates were 73% and 54%, respectively. The 0.5- and 1-year LC rates were 83% and 79%, respectively. In multivariate analysis, higher age (\u2265\u200970\u00a0years), non-vertebral bone metastases, unfavorable primary tumor sites (esophageal cancer, colorectal cancer, hepatobiliary\/pancreatic cancer, renal\/ureter cancer, sarcoma, melanoma, and mesothelioma), lower EBRT dose (BED<jats:sub>10<\/jats:sub>\u2009&lt;\u200939.0\u00a0Gy), and non-administration of bone-modifying agents (BMAs)\/antineoplastic agents after EBRT were significantly unfavorable factors for LC of bone metastases. There was no statistically significant difference in the LC between BED<jats:sub>10<\/jats:sub>\u2009=\u200939.0 and BED<jats:sub>10<\/jats:sub>\u2009&gt;\u200939.0\u00a0Gy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Regarding tumor-related factors, primary tumor sites and the sites of bone metastases were significant for the LC. As for treatment-related factors, lower EBRT doses (BED<jats:sub>10<\/jats:sub>\u2009&lt;\u200939.0\u00a0Gy) and non-administration of BMAs\/antineoplastic agents after EBRT were associated with poor LC. Dose escalation from BED<jats:sub>10<\/jats:sub>\u2009=\u200939.0\u00a0Gy did not necessarily improve LC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01940-0","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T11:02:28Z","timestamp":1637406148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study"],"prefix":"10.1186","volume":"16","author":[{"given":"Kenji","family":"Makita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Uwatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,20]]},"reference":[{"key":"1940_CR1","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/8756-3282(91)90059-R","volume":"1","author":"M Tubiana-Hulin","year":"1991","unstructured":"Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone. 1991;1:S9-10.","journal-title":"Bone"},{"key":"1940_CR2","doi-asserted-by":"publisher","first-page":"25691","DOI":"10.18632\/oncotarget.14823","volume":"8","author":"F De Felice","year":"2017","unstructured":"De Felice F, Piccioli A, Musio D, Tombolini V. The role of radiation therapy in bone metastases management. Oncotarget. 2017;8:25691\u20139.","journal-title":"Oncotarget"},{"key":"1940_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","volume":"24","author":"E Chow","year":"2012","unstructured":"Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112\u20134.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1940_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0167-8140(99)00110-3","volume":"52","author":"E Steenland","year":"1999","unstructured":"Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52:101\u20139.","journal-title":"Radiother Oncol"},{"key":"1940_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","volume":"126","author":"SE Rich","year":"2018","unstructured":"Rich SE, Chow R, Raman S, Liang Zeng K, Lutz S, Lam H, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol. 2018;126:547\u201357.","journal-title":"Radiother Oncol"},{"key":"1940_CR6","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"1940_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342\u201350.","journal-title":"N Engl J Med"},{"key":"1940_CR8","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1097\/BRS.0b013e3181b8b6f5","volume":"34","author":"PC Gerszten","year":"2009","unstructured":"Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine. 2009;34:S78-92.","journal-title":"Spine"},{"key":"1940_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/cam4.292","volume":"3","author":"H Katagiri","year":"2014","unstructured":"Katagiri H, Okada R, Takagi T, Takahashi M, Murata H, Harada H, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3:1359\u201367.","journal-title":"Cancer Med"},{"key":"1940_CR10","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/j.wneu.2017.10.011","volume":"109","author":"BW Smith","year":"2018","unstructured":"Smith BW, Joseph JR, Saadeh YS, La Marca F, Szerlip NJ, Schermerhorn TC, et al. Radiosurgery for treatment of renal cell metastases to spine: a systematic review of the literature. World Neurosurg. 2018;109:e502\u20139.","journal-title":"World Neurosurg"},{"key":"1940_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3171\/2015.11.SPINE151059","volume":"25","author":"JE Leeman","year":"2016","unstructured":"Leeman JE, Bilsky M, Laufer I, Folkert MR, Taunk NK, Osborne JR, et al. Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study. J Neurosurg Spine. 2016;25:52\u20138.","journal-title":"J Neurosurg Spine"},{"key":"1940_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1748-717X-6-34","volume":"6","author":"MA Stinauer","year":"2011","unstructured":"Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34.","journal-title":"Radiat Oncol"},{"key":"1940_CR13","doi-asserted-by":"crossref","first-page":"153303381880647","DOI":"10.1177\/1533033818806472","volume":"17","author":"K Ito","year":"2018","unstructured":"Ito K, Ogawa H, Shimizuguchi T, Nihei K, Furuya T, Tanaka H, et al. Stereotactic body radiotherapy for spinal metastases: clinical experience in 134 cases from a single Japanese institution. Technol Cancer Res Treat. 2018;17:1533033818806472.","journal-title":"Technol Cancer Res Treat"},{"key":"1940_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.prro.2018.11.009","volume":"9","author":"HM McGee","year":"2019","unstructured":"McGee HM, Carpenter TJ, Ozbek U, Kirkwood KA, Tseng TC, Blacksburg S, et al. Analysis of local control and pain control after spine stereotactic radiosurgery reveals inferior outcomes for hepatocellular carcinoma compared with other radioresistant histologies. Pract Radiat Oncol. 2019;9:89\u201397.","journal-title":"Pract Radiat Oncol"},{"key":"1940_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.radonc.2020.01.030","volume":"146","author":"R Singh","year":"2020","unstructured":"Singh R, Lehrer EJ, Dahshan B, Palmer JD, Sahgal A, Gerszten PC, et al. Single fraction radiosurgery, fractionated radiosurgery, and conventional radiotherapy for spinal oligometastasis (SAFFRON): a systematic review and meta-analysis. Radiother Oncol. 2020;146:76\u201389.","journal-title":"Radiother Oncol"},{"key":"1940_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","volume":"133","author":"S Paget","year":"1889","unstructured":"Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;133:571\u20133.","journal-title":"Lancet."},{"key":"1940_CR17","first-page":"715","volume":"48","author":"OV Batson","year":"1942","unstructured":"Batson OV. The vertebral vein system as mechanism for spread of metastases. Am J Roentgenol Radium Ther Nucl Med. 1942;48:715\u20138.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"1940_CR18","doi-asserted-by":"publisher","first-page":"15182","DOI":"10.18632\/oncotarget.14858","volume":"8","author":"IH Jung","year":"2017","unstructured":"Jung IH, Yoon SM, Kwak J, Park JH, Song SY, Lee SW, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget. 2017;8:15182\u201392.","journal-title":"Oncotarget"},{"key":"1940_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10147-019-01591-y","volume":"25","author":"K Makita","year":"2020","unstructured":"Makita K, Hamamoto Y, Tsuruoka S, Takata N, Urashima Y, Miyagawa M, et al. Treatment intensity and control rates in combining external-beam radiotherapy and radioactive iodine therapy for metastatic or recurrent differentiated thyroid cancer. Int J Clin Oncol. 2020;25:691\u20137.","journal-title":"Int J Clin Oncol"},{"key":"1940_CR20","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.2005.05.0542","volume":"24","author":"D Rades","year":"2006","unstructured":"Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24:3388\u201393.","journal-title":"J Clin Oncol"},{"key":"1940_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijrobp.2019.11.401","volume":"106","author":"D Rades","year":"2020","unstructured":"Rades D, Cacicedo J, Conde-Moreno AJ, Segedin B, But-Hadzic J, Groselj B, et al. Precision radiation therapy for metastatic spinal cord compression: final results of the PRE-MODE trial. Int J Radiat Oncol Biol Phys. 2020;106:780\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1940_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00066-012-0158-4","volume":"188","author":"D Rades","year":"2012","unstructured":"Rades D, Hakim SG, Bajrovic A, Karstens JH, Veninga T, Rudat V, et al. Impact of zoledronic acid on control of metastatic spinal cord compression. Strahlenther Onkol. 2012;188:910\u20136.","journal-title":"Strahlenther Onkol"},{"key":"1940_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","volume":"67","author":"V Vassiliou","year":"2007","unstructured":"Vassiliou V, Kalogeropoulou C, Christopoulos C, Solomou E, Leotsinides M, Kardamakis D. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys. 2007;67:264\u201372.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1940_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/jrr\/rraa020","volume":"61","author":"H Tanaka","year":"2020","unstructured":"Tanaka H, Makita C, Manabe Y, Kajima M, Matsuyama K, Matsuo M. Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. J Radiat Res. 2020;61:494\u20138.","journal-title":"J Radiat Res"},{"key":"1940_CR25","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/1097-0142(19861215)58:12<2589::AID-CNCR2820581206>3.0.CO;2-O","volume":"58","author":"V Scheid","year":"1986","unstructured":"Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986;58:2589\u201393.","journal-title":"Cancer"},{"key":"1940_CR26","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335:1785\u201391.","journal-title":"N Engl J Med"},{"key":"1940_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/bjc.1998.54","volume":"77","author":"EF Smit","year":"1998","unstructured":"Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347\u201351.","journal-title":"Br J Cancer"},{"key":"1940_CR28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/028418501127346503","volume":"42","author":"I Ciray","year":"2001","unstructured":"Ciray I, Lindman H, Astr\u00f6m KG. Early response of breast cancer bone metastases to chemotherapy evaluated with MR imaging. Acta Radiol. 2001;42:198\u2013206.","journal-title":"Acta Radiol"},{"key":"1940_CR29","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00280-013-2148-3","volume":"71","author":"T Tokito","year":"2013","unstructured":"Tokito T, Shukuya T, Akamatsu H, Taira T, Ono A, Kenmotsu H, et al. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. Cancer Chemother Pharmacol. 2013;71:1493\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1940_CR30","first-page":"171","volume":"63","author":"HT Mouridsen","year":"1979","unstructured":"Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, Rose C. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep. 1979;63:171\u20135.","journal-title":"Cancer Treat Rep"},{"key":"1940_CR31","first-page":"3434s","volume":"42","author":"A Lipton","year":"1982","unstructured":"Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res. 1982;42:3434s-s3436.","journal-title":"Cancer Res"},{"key":"1940_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/1097-0142(19860701)58:1<7::AID-CNCR2820580103>3.0.CO;2-#","volume":"58","author":"H van Veelen","year":"1986","unstructured":"van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT. Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer. 1986;58:7\u201313.","journal-title":"Cancer"},{"key":"1940_CR33","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1136\/bmj.283.6304.1432","volume":"283","author":"IE Smith","year":"1981","unstructured":"Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed). 1981;283:1432\u20134.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1940_CR34","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1994.12.8.1630","volume":"12","author":"HB Muss","year":"1994","unstructured":"Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Gansauer L, Moore LA, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol. 1994;12:1630\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-021-01940-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T23:07:29Z","timestamp":1637449649000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,20]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1940"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01940-0","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,20]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients treated at Shikoku Cancer Center, Ehime University Hospital, and Saiseikai Imabari Hospital consented in writing for the use of their anonymous data for research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}